PCR Testing Started in Indonesia in order to Prevent the Spread of the Novel Coronavirus (COVID-19)

Toyota Tsusho Corporation extends our deepest condolences to all those in countries around the world who lost their lives due to COVID-19, the infectious disease caused by the novel coronavirus, as well as our heartfelt sympathy to those who are currently fighting the disease.

In addition, we express our sincere respect for all medical professionals doing their best to diagnose and treat patients at the frontline toward preventing the spread of COVID-19.

Toyota Tsusho Corporation (Toyota Tsusho) announced today that its joint venture PT. Innolab Sains Internasional (ISI) has started PCR testing in Indonesia to prevent the worsening spread of COVID-19, the infectious disease caused by the novel coronavirus, after receiving an official request from Indonesia's Ministry of Health.

ISI is a company conducting subcontracted clinical laboratory testing. ISI is a joint venture between Toyota Tsusho, Health Sciences Research Institute, Inc., and Indonesian conglomerate and Southeast Asia's largest pharmaceutical manufacturer PT. Kalbe Farma Tbk.

The PCR testing will be conducted at KALGen Innolab Clinical Laboratory, operated by ISI.

Going forward, Toyota Tsusho Group will continue to contribute toward preventing the spread of COVID-19 through collaboration with the governments of the respective countries.

Profile of PT. Innolab Sains Internasional

PT. Innolab Sains Internasional
December 2017
Jakarta, Indonesia
31,668 million rupiah
Line of business
Subcontracted clinical laboratory testing in Indonesia